White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-07-31

Study Completion Date

2017-04-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: It is not yet know whether white wine is more effective than a nutritional supplement in improving appetite.

PURPOSE: This randomized clinical trial is studying white wine to see how well it works compared with a nutritional supplement in improving appetite in patients with cancer

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer

NCT00053053

Cachexia Lymphoma Lymphoproliferative Disorder +1 more

COMPLETED PHASE3

Low Antioxidant Diet in Controlling Cachexia in Patients With Oropharyngeal Cancer Receiving Chemotherapy and Radiation Therapy

NCT00486304

Cachexia Head and Neck Cancer Weight Changes

COMPLETED PHASE1

Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients

NCT00851448

Cachexia Cancer

TERMINATED NA

Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer

NCT00006799

Anorexia Cachexia Head and Neck Cancer +1 more

COMPLETED PHASE3

Beta-carotene and Alpha-tocopherol Chemoprevention of Second Primary Malignancies in Head and Neck Cancer Patients

NCT00169845

Neoplasms

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

I. To compare white wine (Arm A) to non-wine nutritional supplement (Arm B) for the treatment of cancer-associated anorexia.

II. To evaluate the side effect profile of white wine (Arm A).

OUTLINE: Patients are stratified according to primary malignant disease (lung vs gastrointestinal vs other \[specify\]), severity of weight loss (excluding peri-operative weight loss) within the past 2 months (\< 4.6 kg \[\< 10 lbs\] vs \>= 4.6 kg \[\>= 10 lbs\]), age (\< 50 years vs \>= 50 years), and planned concurrent chemotherapy or radiation (yes vs no).

Patients are randomized to 1 of 2 arms.

ARM A: Patients consume white wine with =\< 15% alcohol content twice daily for 3-4 weeks.

ARM B: Patients receive an oral non-wine nutritional supplement (e.g., Boost or Ensure) twice daily for 3-4 weeks.

After completion of study treatment, patients are followed up every 6 months for 2 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Unspecified Adult Solid Tumor, Protocol Specific

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A (white wine)

Patients consume white wine twice daily for 3-4 weeks.

Group Type EXPERIMENTAL

white wine

Intervention Type DIETARY_SUPPLEMENT

Given orally

questionnaire administration

Intervention Type OTHER

Ancillary studies

Arm B (non-wine nutritional supplement)

Patients receive an oral non-wine nutritional supplement (e.g., Boost or Ensure) twice daily for 3-4 weeks.

Group Type ACTIVE_COMPARATOR

therapeutic nutritional supplementation

Intervention Type OTHER

Given orally

questionnaire administration

Intervention Type OTHER

Ancillary studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

therapeutic nutritional supplementation

Given orally

Intervention Type OTHER

white wine

Given orally

Intervention Type DIETARY_SUPPLEMENT

questionnaire administration

Ancillary studies

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Incurable, invasive malignancy
* Able to reliably take the study intervention as prescribed in this protocol
* No prior or current history of alcoholism
* Alert and mentally competent
* Physician estimates that patient has lost \>= 5 pounds (2.3 kg) in weight =\< 2 months (excluding peri-operative weight loss; documented weight loss not required) and/or have estimated caloric intake of \< 20 cal/kg daily (no further documentation necessary other than an affirmative answer to this statement)
* Patient perceives loss of appetite and/or weight as a problem; NOTE: Documentation not necessary
* Concurrent chemotherapy and/or radiotherapy are permitted
* Negative pregnancy test done =\< 7 days prior to registration, for women of childbearing potential only
* Willingness to abstain completely from alcohol for 4 weeks, except as prescribed in this trial; NOTE: Patients assigned to the non-wine nutritional supplement (Arm B) must be willing to abstain from wine and other alcoholic beverages for 3-4 weeks; Patients assigned to the white wine (Arm A) are allowed to take a nutritional supplement, such as Ensure or Boost if they choose to
* Ability to complete questionnaire(s) by themselves or with assistance
* Willingness to return to MCCRC enrolling institution for follow-up
* Patients in whom the use of progestational agents is anticipated are not permitted to be on this study
* Short-term use of dexamethasone around days of intravenous chemotherapy is allowed for protection against emesis, but dexamethasone for appetite stimulation is not permitted

Exclusion Criteria

* Receiving tube feedings or parenteral nutrition
* Current (=\< 1 month) or planned treatment with adrenal corticosteroids (short-term use of dexamethasone around days of chemotherapy is allowed for protection against emesis), androgens, or progestational agents; EXCEPTION: Inhalant, topical, or optical steroid use is permissible
* Progestational agent (such as megestrol acetate) planned to be initiated over the next 30 days; NOTE: Patients who have been on megestrol acetate for \> 1 month and are still on it and otherwise meet the eligibility criteria are permitted to enroll on this protocol and remain on megestrol acetate
* Known mechanical obstruction of the alimentary tract, malabsorption, or intractable vomiting (\> 5 episodes/week)
* Symptomatic or untreated brain metastases
* Any of the following as this regimen may be harmful to a developing fetus or nursing child: pregnant women, nursing women, and men or women of childbearing potential who are unwilling to employ adequate contraception

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No